Haleon Pakistan Limited engages in the manufacture, marketing, and sale of consumer healthcare products in Pakistan, rest of Asia, Africa, Australia, North America, the Middle East, and Europe. The company offers oral health, pain relief, wellness and nutrition, and respiratory health products, as well as over-the-counter pharmaceutical products. It sells its products primarily under the Panadol, CaC-1000 Plus, Sensodyne, paradontax, T-Day, ENO, Hydrozole, Qalsium-D, and Voltral Emulgel brands. The company also exports its products to Vietnam, the Philippines, and East West Africa region. The company was formerly known as GlaxoSmithKline Consumer Healthcare Pakistan Limited and changed its name to Haleon Pakistan Limited in January 2023. Haleon Pakistan Limited was incorporated in 2015 and is headquartered in Karachi, Pakistan. Haleon Pakistan Limited is a subsidiary of Glaxosmithkline Consumer Healthcare B.V.
Metrics to compare | HALE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipHALEPeersSector | |
---|---|---|---|---|
P/E Ratio | 18.1x | 19.6x | 11.8x | |
PEG Ratio | 0.06 | 0.03 | 0.03 | |
Price/Book | 8.2x | 1.3x | 1.5x | |
Price / LTM Sales | 2.4x | 1.5x | 0.9x | |
Upside (Analyst Target) | - | 20.9% | 17.8% | |
Fair Value Upside | Unlock | 9.2% | 11.0% | Unlock |